Members of the 2015–2018 Research Committee of the National Health and Medical Research Council (NHMRC) are appointed until 30 June 2018.


Professor Kathryn North


Professor Kathryn North AM is Director of the Murdoch Children's Research Institute and the David Danks Professor of Child Health Research at the University of Melbourne.

Professor North is trained as a paediatric physician, neurologist and clinical geneticist. Her laboratory research interests focus on inherited muscle disorders. Her clinical research focuses on clinical trials of therapies for muscular dystrophy as well as the development of interventions for children with learning disabilities. In 2012, Professor North was appointed as Chair of the NHMRC Research Committee and a Member of NHMRC Council.


Nil apart from institutional affiliations and current NHMRC funding.

Professor Warren Alexander


Professor Warren Alexander received his PhD in medical biology from the University of Melbourne, and his post-doctoral studies were completed at the Research Institute for Molecular Pathology in Vienna, Austria and the Ludwig Institute for Cancer Research in Melbourne.

Since 1994, he has been a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research (WEHI) and is currently Joint Head of the Cancer and Haematology Division.

An NHMRC Senior Principal Research Fellow, Professor Alexander's research focuses on the molecular regulation of blood cell production and function.


  • I am an active researcher, Joint Head of the Cancer and Haematology Division and member of the Senior Scientific Advisory Team of the Walter and Eliza Hall Institute of Medical Research.
  • I hold an honorary Professorial position at the University of Melbourne
  • I am Chief Investigator on NHMRC Program and Project Grants and hold an NHMRC Fellowship. I receive research funding and/or benefit from grants from other funding sources and from private philanthropy.
  • I hold shares in and am co-chair of the Scientific Advisory Board of Murigen Therapeutics.
  • I am a member of the Children’s Cancer Institute Australia Scientific Advisory Committee.
  • I am a current member of NHMRC Research Committee and sub-committees thereof.
  • I am a member of the American Society of Hematology Scientific Committee on Hematopoiesis (2014–2017)
  • I am a member in 2016 of the Australian Society for Biochemistry and Molecular Biology (ASBMB), the Australian Society for Medical Research (ASMR), the American Society of Hematology, the International Society for Stem Cell Research (ISSCR) and the Society for Hematology and Stem Cells (ISEH).
  • I am a member of the Cancer Council Victoria Venture Grants Committee.
  • I regularly publish in the field of molecular haematology and related disease areas, details of which can be found in PubMed or the publications repository of The Walter and Eliza Hall Institute of Medical Research.
James Bourne

Associate Professor

Associate Professor James Bourne (NHMRC Senior Research Fellow) is a Senior Group Leader at the Australian Regenerative Medicine Institute, Monash University. James originally trained in Biochemistry at the Imperial College of Science, Technology and Medicine (London) before focusing on a career in neuroscience. He has emerged as a world-renowned leader in the development and regeneration of the primate visual system and has been the recipient of both ARC and NHMRC Fellowships and Grants.


Recipient of NHMRC CDF II and SRFA Recipient of NHMRC Project Grants since 2008 Recipient of ARC Fellowship and Discovery Projects Previous member of Academy (2012–2015) Previous member of Postdoc. Reference Group Served as member of GRP 2008, 2009, 2010, 2011 Served as member of DGRP 2014, 2015 Chair, National Nonhuman Primate Breeding and Research Facility Member of a number of Academic journal boards.

Jeffrey Braithwaite


Professor Jeffrey Braithwaite, BA, MIR (Hons), MBA, DipLR, PhD, FAIM, FCHSM, FFPHRCP (UK) is Foundation Director, Australian Institute of Health Innovation, Director, Centre for Healthcare Resilience and Implementation Science, and Professor of Health Systems Research, Faculty of Medicine and Health Sciences, Macquarie University, Australia. His research examines the changing nature of health systems, particularly patient safety, standards and accreditation, leadership and management, the structure and culture of organisations and their network characteristics, attracting funding of more than AUD$59 million.

Professor Braithwaite has published extensively (more than 600 total publications) and he has presented at international and national conferences on more than 780 occasions, including over 75 keynote addresses. He has conducted research over two decades on clinical and organisational performance, health systems improvement and patient safety as part of his interests in health services research and translational, implementation science. Professor Braithwaite recently co-edited a book with Professors Erik Hollnagel in Denmark and Bob Wears in the United States (Resilient Health Care, Ashgate, 2013), which proposes new models for tackling patient safety. A second book in the series, The Resilience of Everyday Clinical Work, was published in 2015. He led work culminating in the publication of a compendium (Ashgate, 2015) on health systems improvement across the world: Healthcare Reform, Quality and Safety: Perspectives, Participants, Partnerships and Prospects in 30 Countries.


  • Professor of Health Systems Research, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia Appointed 2014 to present
  • Foundation Director, Australian Institute of Health Innovation Faculty of Medical and Health Sciences, Macquarie University, 2014–present (previously, UNSW 2007–2014)
  • Director, Centre for Healthcare Resilience and Implementation Science Faculty of Medical and Health Sciences, Macquarie University, 2014–present (previously, UNSW 2001–2014)
  • Visiting or Honorary Professor at: UNSW; University of Stavanger; University of Birmingham; University of Newcastle upon Tyne; University of Southern Denmark
  • Royal Australasian College of Medical Administrators Board Member, 2012–present
  • The Baird Institute for Cardiothoracic Research Board Member, 2009–present
  • Health Statistics, New South Wales Admitted Patient Report Member of Reference Group, 2009–present
  • Between the Flags Evaluation Collaborative Committee Member, 2011–present
  • Member of NHMRC Academy NHMRC’s Peer Review Process, 2011–present
  • Climate and Health Alliance [CAHA] Founding Member, 2010–present
  • National Health and Medical Research Council External Assessor, 2003–present
  • Australian Research Council Assessor
  • AIHI Communities of Practice and Social Professional Networks ARC Discovery Grant Reference Group Chair, 2009–present
  • AIHI NHMRC Patient Safety Program Grant Management Committee Chair, 2009–present
  • National Health and Medical Research Council, Program Grant [APP ID 1054146], 2014–2018
  • National Health and Medical Research Council, Partnership grant [App ID 1065898], 2013–2016
  • BUPA Health Foundation, Industry grant, 2013
  • NSW Health, Industry grant, 2013:
  • National Health and Medical Research Council, Partnership grant, 2012–2015
  • Cancer Institute, NSW, Centre grant, 2011–2016


Professor Peter Ebeling is Head, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University. He is also Inaugural Director of the Australian Institute of Musculoskeletal Science (AIMSS). Research interests include musculoskeletal health and diseases; public health aspects of Vitamin D, post-transplantation osteoporosis; osteoporosis in men; and biochemical bone turnover markers.

Professor Ebeling was Associate Editor of Journal of Bone and Mineral Research from 2008–2012. He currently serves on the Editorial Board of Osteoporosis International and is Editor of Clinical Endocrinology (Oxf) and Editor-in-Chief of Bone Reports. He is Medical Director of Osteoporosis Australia; Board Member, International Osteoporosis Foundation; Past-President, Endocrine Society of Australia; Past-President of the Australian and New Zealand Bone and Mineral Society; and Past-Councillor, American Society of Bone and Mineral Research, only the third Australian to be elected.

He is on the NHMRC Academy (2009–2014). He has over 230 peer-reviewed publications, including in the New England Journal of Medicine, PNAS (USA) and Science.

He also teaches and mentors medical students, and supervises a number of Research Higher Degree students, and advanced physician trainees in Endocrinology.


  • Departmental research funding from Amgen
  • Departmental research funding from Merck
  • Departmental research funding from Eli-Lilly
  • Departmental research funding from Novartis
  • Honoraria for speaking from Amgen
  • Honoraria for speaking from Eli-Lilly
  • Honoraria for speaking from Merck
  • Honoraria for speaking from GSK and ViiV Healthcare
  • Advisory Board membership UCB
  • Head, Department of Medicine, School of Clinical Sciences, Monash University
  • Chair, Division of Medicine, Monash Health
  • Endocrinologist, Department of Endocrinology, Monash Health
  • Board Member, Osteoporosis Australia 2005–
  • Board Member, International Osteoporosis Foundation
  • Editor-in-Chief, Bone Reports, Elsevier
  • Editor, Clinical Endocrinology (Oxford)
  • Advisory Board, Amgen
  • Advisory Board, Eli-Lilly
  • Advisory Board, Radius
Professor Tim Hughes


Professor Tim Hughes is Cancer Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) and Beat Cancer Professor at the University of Adelaide. He is also a Consultant Haematologist at SA Pathology and the Royal Adelaide Hospital. He is a Fellow of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australia as well as a Fellow of the Australian Academy of Health and Medical Sciences. His major research interest are targeted therapies for leukaemia, molecular monitoring of response to therapy, and drug resistance mechanisms


  • Chair of the International Chronic Myeloid Leukaemia Foundation
  • Talks at pharmaceutical meetings and symposia
  • Cancer Theme Leader at the South Australian Health and Medical Research Institute
  • Research Grant funding from Novartis, BMS and Ariad
  • Pharma support to enable me to attend scientific meetings. Companies include Novartis. BMS and Ariad
  • NHMRC Practitioner Fellowship from 2008 to 2012 and 2013 until 2017 in the area of CML biology and therapy
  • Program Grant 2015 to 2019 on the topic of cytokine regulation in leukaemia
  • Current and future applications for various research and people grants through the NHMRC
  • Past and current member of the Australasian Leukaemia and Lymphoma Group (ALLG)
  • Beat Cancer Professorial Chair at the University of Adelaide
  • Consultant Haematologist at SA Pathology, South Australia
  • On the global study management committee for various Novartis clinical trials
Professor Maria Kavallaris


Professor Maria Kavallaris is Head of the Tumour Biology and Targeting Program at the Children’s Cancer Institute and Director of the Australian Centre for NanoMedicine at the University of New South Wales. Her research contributions in cancer biology and therapeutics are internationally recognised. She leads a multidisciplinary research program that investigates how tumours form, grow and spread and she applies this knowledge to develop effective and less toxic cancer therapies using nanotechnology.

Professor Kavallaris has served on numerous committees including the Program Committee for the Annual Meeting of the American Association for Cancer Research and NHMRC Assigners Academy. She is Chair of the Board of the Australian Institute for Policy and Science and has played a major role in advocating for medical research through public outreach and served as President of the Australian Society for Medical Research. Professor Kavallaris was recognised by the NHMRC as part of its rollcall of Australian ‘high achievers’ in health and medical research (past and present) in 2014.


  • Chair, Australian Institute for Policy and Science – non-remunerated role
  • Employed as Program Head, Tumour Biology and Targeting Program, Children's Cancer Institute Director, Australian Centre for NanoMedicine, University of New South Wales (non-remunerated)
  • NHMRC Program Grant NHMRC Senior Research Fellowship ARC Centre of Excellence ARC Discovery Project ARC Linkage Projects (x2) Cancer Council NSW Program Grant The Kids Cancer Project – research grant
  • Collaboration part of ARC Linkage project to develop a 3D cell printing platform
  • Appointed to ASMR Research Fund Executive Committee
Professor Bronwyn Kingwell


Professor Bronwyn Kingwell is a NHMRC Senior Principal Research Fellow, and at the Baker IDI Heart and Diabetes Institute is Executive Director, Science Policy, Domain Leader for Prevention and also leads the Metabolic and Vascular Physiology Laboratory. She has Professorial appointments in the Department of Medicine and Department of Physiology at both the University of Melbourne and Monash University, at James Cook University, the University of NSW and the University of Pierre and Marie Curie in Paris. She received her PhD in physiology from the University of Melbourne in 1991.

As an integrative clinical physiologist, Professor Kingwell has made contributions to the understanding of the pathophysiology of diabetes and cardiovascular disease and the preventive and therapeutic effects of exercise. This includes her research into HDL and glucose metabolism which is informing the development of therapeutics directed at HDL. Her contributions have also influenced national and international physical activity guidelines.

Professor Kingwell has held leadership roles on the NHMRC Council and Research Committee, the National Heart Foundation Research Committee and the National Committee for Medicine of the Australian Academy of Science.


  • Resverlogix Corp Research grant – Investigator initiated trial – direct research costs, but not labor – $A323,056 Travel support – $US5,000 (all paid to Baker IDI Heart and Diabetes Institute)
  • Kowa Group Research grant – Investigator-initiated research funding – (paid to Baker IDI Heart and Diabetes Institute)
  • CSL Limited Research grant – Investigator Initiated Trial – $25,000 (Paid to Baker IDI Heart and Diabetes Institute) Supply of reconstituted HDL for research studies
  • Consultancy fees paid to Baker IDI Heart and Diabetes Institute from CSL Limited to partially fund travel for conference presentations
  • Employee of Baker IDI Heart and Diabetes Institute since 1991 and funded by NHMRC fellowships and Baker IDI Heart and Diabetes Institute.
  • NHMRC funding: Fellowship, Program grant, Project grant, CRE grants
  • Honorary Professor, Monash University (Physiology and Medicine)
  • Honorary Professor, University of Melbourne (Physiology)
  • Honorary Professor, University of New South Wales
  • Honorary Professor, James Cook University
Professor Peter Leedman


Professor Peter Leedman is the Director of the Harry Perkins Institute of Medical Research (‘Perkins’) in Perth and Professor of Medicine (endocrinologist) at the University of Western Australia (UWA). He completed medicine at UWA, endocrinology at Royal Melbourne Hospital, his PhD at WEHI and a post-Doc at Harvard Medical School. Upon returning to Perth, he was instrumental in the establishment of the Perkins (formerly the Western Australian Institute for Medical Research) and the development of its two new state-of-the-art research buildings.

Leedman’s research has a core interest in RNA biology with a translational focus to devise novel RNA-based therapeutic approaches to abrogate the growth of hormone-dependent cancers, melanoma, head and neck, liver and colon cancer. Leedman co-founded miReven, a spin out company established to bring microRNA replacement therapy for liver cancer to the bedside.

Leedman has served on numerous NHMRC and other committees and is currently Chairman of the Sylvia and Charles Viertel Foundation Medical Advisory Committee and of Linear Clinical Research Ltd, the Perkins 24 bed phase 1 clinical trials facility.


Chairman of Linear Clinical Research Ltd, and some other Scientific Committees Have received several NHMRC grants Publish papers Director of a medical research institute.

Dr McAullay

Associate Professor

Dr McAullay has considerable experience in health research, policy and practice. He has worked in a number of senior positions in these areas as well as in tertiary education. He is a registered nurse with qualifications including a Doctor of Philosophy, a Master of Applied Epidemiology and a Bachelor of Science. He has provided advice to a number of Government departments and non-Government organisations, including large research institutes and has sat on a number of committees providing advice to State and Commonwealth Government in the area of health. He has a strong health research track record including presentations, publications and grants. His primary research areas of interest include maternal, infant and child health, primary health care and other health services research.

He currently works as Research Associate Professor at the Centre for Improving Health Services for Aboriginal Children (Princess Margaret Hospital/ University of Western Australia) and as the Principal Research Consultant at Kurongkurl Katitjin, Centre for Indigenous Australian Education and Research at Edith Cowan University. He also runs his own consulting company (Dan McAullay Consulting) and consults with the wholly Australian Aboriginal and Torres Strait Islander owned and managed consulting company, DDMC Partners.


  • Working with CI to manage the Project grant and assist with a CRE.
  • Past consultancies have included work for WA and ACT Government departments and NGOs
  • CI on Grants with Karen Edmond, Bridgette McNamara and Jonathan Carapetis
  • Two published documents relate to the development of the Values and Ethics Guidelines.
  • Friendships through current and past working relationships
  • I have a consulting business with Sister of an NHMRC employee
  • Employed as Adjunct Associate Professor/ Principal Research Consultant at Kurongkurl Katitjin, Edith Cowan University
  • Child and Adolescent Health Service Board – Department of Health Western Australia
Professor Sandy Middleton


Professor Sandy Middleton is Director of the Nursing Research Institute a joint initiative between Australian Catholic University and St Vincent's Health Australia, located in Sydney. Professor Middleton has a particular interest in stroke and implementation research with approximately $17m awarded in competitive grant funding over her career to date. She is the currently the lead investigator on the NHMRC funded T3 Trial: Triage, Treatment and Transfer of patients with stroke in Emergency Departments. She also was the lead investigator on the Quality in Acute Stroke Care (QASC) Implementation Project which was awarded the NSW Premier's 2014 Public Sector Award for Improving Performance and Accountability.

Professor Middleton is a member of the NHMRC Research Translation Faculty and the Cardiovascular and Stroke ‘Call for Action’ Steering Group. She also is a member of the Australian Commission on Safety and Quality in Health Care Stroke Clinical Care Standard Topic Working Group. Professor Middleton is the Chair of the Steering Committee of the Australian Stroke Clinical Registry and a member of the Board of Directors for the Clinical Excellence Commission and the NSW Agency for Clinical Innovation


  • Board Membership (NSW Clinical Excellence Commission; NSW Agency for Clinical Innovation, St Vincent's Clinic)
  • National Stroke Foundation: Clinical Council and Guidelines Development Working Group. Australian Commission on Safety and Quality in Health Care, Stroke Clinical Care Standard Topic Working Group, Jan 2013 to July 2015 Australian Stroke Coalition, Executive Committee; and Data and Quality Working Group 2013 to present. Stroke Society of Australasia, Executive Committee, Nov 2011 to Sept 2015 Research Committee, NSW Clinical Excellence Commission; NSW Agency for Clinical Innovation, Nov 2011 to present. Australian Stroke Clinical Registry, Chair Steering Committee, Oct 2008 to present Acute Stroke Nursing Education Network, Co-Chair April 2012 to Sept 2015
  • Australian Catholic University, Employment, 2005 to present St Vincent's Hospital, Employment, 2008 to present
  • NHMRC PhD Scholarship (Dora Lush); NHMRC Project Grants x 8; NHMRC Partnership Grants x 3; and CRE Grant x 1; ARC grants
  • Occasional meals funded by Boehringer Ingelheim as part of educational meetings
  • Multiple peer reviewed publications Australian Commission on Safety and Quality in Health Care, Stroke Clinical Care Standard 2015
  • Boehringer Ingelheim, small unrestricted educational grant ($20,000) to set up the Acute Stroke Nurses Education Network (Co-Chair). No funds were received by myself or my institutions.
Prof Ben Solomon


Prof Ben Solomon is a Medical Oncologist at Peter MacCallum Cancer Centre in Melbourne and an Associate Professor of Medicine at the University of Melbourne. He has an interest in clinical and translational research in lung cancer. After completing his specialty training in medical oncology he undertook a PhD in investigating the mechanisms by which EGFR inhibition enhance the effects of radiation in Melbourne and subsequent postdoctoral studies at the University of Colorado investigating novel predictive markers for therapy with EGFR inhibitors. He returned to Peter MacCallum Cancer Centre in 2006 where he practices as a Medical Oncologist with a clinical research focus on clinical and translational research in lung and head and neck cancer and phase I studies of novel anti-cancer therapies. He also leads a laboratory research group within the Molecular Therapeutics and Biomarkers laboratory in the Research Division.

His research accomplishments include identification of novel biomarkers of potential clinical relevance in lung cancer and head and neck cancer and conduct of clinical trials of novel therapies in lung cancer. This includes the conduct of clinical and translational studies defining ALK gene rearrangements as a therapeutic target in non-small cell lung cancer. This work included a leadership role in the key phase I, II, and III trials with ALK inhibitors and resulted in a change in the standard of care for this patient population. He continues to undertake trials with novel targeted therapies and work to define predictive and prognostic markers for patients with lung cancer.


  • Research Funding from Pfizer Preclinical studies with Palbociclib
  • Pfizer Advisory Board
  • Novartis Advisory Board
  • AstraZeneca advisory board
  • AstraZeneca Travel support to attend American Society for Clinical Oncology meeting
  • Roche advisory board
  • Merck Sharpe Dohme advisory boards
  • Bristol Myers Squibb Advisory Board
Laureate Professor Talley


Laureate Professor Talley is currently Pro Vice-Chancellor, Global Research and Professor of Medicine at the University of Newcastle, Australia. He is an expert clinician, educator and researcher, with extensive experience as a leader in the medical and University sectors. He previously held an appointment as Pro Vice-Chancellor (and Dean) of the Faculty of Health and Medicine at the University of Newcastle from 2010–2015, and was seconded to be the Deputy Vice-Chancellor-Research (Acting) at the University of Newcastle from June 2013 to March 2014.

Professor Talley has published over 800 original and review articles in the peer-reviewed literature. He is also a leading medical educator and the author of the highly regarded textbooks Clinical Examination and Examination Medicine. In June 2014, Professor Talley was inaugurated as one of the first 15 Fellows of the Australian Academy of Health and Medical Sciences (FAHMS) and was elected to the Executive of the Academy.

Professor Talley is currently a Senior Staff Specialist and gastroenterologist at John Hunter Hospital and attends clinic and lists on a weekly basis.


University of Newcastle, Pro Vice-Chancellor Medical Journals of Australia, Editor in Chief Committees of the Presidents of Medical Colleges, Chair.

Professor Teede


Professor Teede MBBS, FRACP PhD, is a clinical and public health researcher with an NHMRC Practitioner Fellowship. Professor Teede is a clinician/ endocrinologist and public health specialist focused on women’s reproductive and metabolic health. She is a past member of the NHMRC’s National Health Care Committee, NHMRC CEO Advisory Committee on Translation, Chair of the NHMRC National Faculty for Research Translation Steering Committee for Diabetes and a member of the Obesity Committee. President of the Endocrine Society of Australia, Professor of Women’s Health and Director of the Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine and Professor of the Diabetes and Vascular Medicine at Monash Health. She recently became the Executive Director of the NHMRC accredited Monash Partners Academic Health Sciences Centre.

Professor Teede established and leads the National Australian Polycystic Ovary Syndrome Alliance, is on the steering committee of the National Partnership for Indigenous Women’s Health and is a past board member for Diabetes Australia with significant NGO engagement.


  • Employee and senior academic of Monash University – since 1997 funded by NHMRC fellowships and Monash University
  • Board member, Diabetes Australia, Victoria – voluntary position 2009–2014
  • Industry partnership with funds to the institution: Industry funding – pharmaceutical trials funded on a per patient basis
  • Funding: NHMRC, National Heart Foundation (NHF), Diabetes Australia Research Trust (DART), Department of Health-Victorian Government, International Diabetes Federation (IDF), Buckland, Perpetual Trustees, Lew Carty and Helen McPherson Trust, Brockhoff Trust, Cancer Australia
  • Practice: practising endocrinologist in public practice. Primary appointment at Monash Health
  • Owner/Director of Epworth Sleep Centre
Professor Rosalie Viney


Professor Rosalie Viney is Professor of Health Economics and Director of the Centre for Health Economics Research and Evaluation at the University of Technology Sydney. She has extensive experience in health economics, health services and health policy research. Her research interests include health technology assessment and priority setting, measurement and valuation of quality of life and health outcomes, consumer preferences for health and health care, evaluation of health policy, and the impact of funding arrangements on utilisation and outcomes of health care. Rosalie has undertaken a broad range of commissioned projects for State/Territory Health authorities, and for the Australian Government Department of Health. She is the program leader for the Cancer Australia funded national technical service providing health economics expertise and capacity building to national Cancer Clinical Trials Groups. Rosalie has also had longstanding involvement in the development of the fields of health economics and health services research in Australia, through the Australian Health Economics Society and the Health Services Research Association of Australia and New Zealand. She is also a long-standing member of the Pharmaceutical Benefits Advisory Committee (PBAC) and Chair its Economics Sub-Committee


  • Professor of Health Economics and Director, Centre for Health Economics Research and Evaluation at University of Technology, Sydney (employed by UTS in this and related roles since 2003)
  • Membership of the EuroQOL group is by application and requires active and ongoing research using the EQ-5D instrument. The EuroQOL group provides travel support for attendance at meetings and members can apply for competitive research funding on topics related to measurement and valuation of quality of life using the EQ-5D.
  • Membership of Pharmaceutical Benefits Advisory Committee (since 2005) and of the Economics Sub-Committee of PBAC (since 2001)
  • Program Leader for the National Technical Service for provision of health economics advice to Cancer Clinical Trials Groups. This program of research is funded by Cancer Australia and provided as competitive funding to the Centre for Health Economics Reseach and Evaluation.
  • Researcher in health technology assessment, quality of life valuation and measurement, economic evaluation, quantitative health policy evaluation, measurement of consumer preferences.
  • My Centre has submitted a NHMRC Sustainability Partnership Centre Application. I am not a Chief Investigator but I am named on the bid, and my Centre would benefit.
Patsy Yates


Professor Patsy Yates is jointly appointed as Head, School of Nursing at Queensland University of Technology and Director for Queensland Health's statewide Centre for Palliative Care Research and Education (CPCRE).

She has over 30 years' experience in research, education and clinical practice in cancer and palliative care. She leads a range of research and service improvement programs focused on developing workforce capacity in cancer and palliative care, advancing the management of cancer related symptoms and treatment side effects, and strengthening the nexus between research, policy and practice in cancer care. She is currently President for Palliative Care Australia.


  • Employed as Professor or Nursing and Head of School at Queensland University of Technology Jointly appointed as Director, Queensland Health Centre for Palliative Care Research and Education Honorary appointments as Visiting Researcher, Princess Alexandra Hospital and Royal Brisbane and Women's Hospital
  • Current Board Memberships: Palliative Care Australia; Nursing and MIdwifery Board of Queensland (Previously Queensland Nursing Council); Asia Pacific Hospice-Palliative Care Network; International Society of Nurses in Cancer Care Previous Board memberships: National Breast and Ovarian Cancer Centre Board Member; International Society of Nurses in Cancer Care
  • Served on a range of committees/review panels for which I received honoraria or assessment fees
  • Current Grants : NHMRC Centre for Research Excellence App: 1060254; App: 1079502; NHMRC Partnership Grants App: 1041640; NHMRC Project Grants App: 1041640; Previous NHMRC funding since 1998
  • Current, past ARC grants: CP15100414; LP120200268; LP0882338; LP0669670;
  • Other current grant funding: RBWH Research Foundation; PA Research Foundation Grants: Australian Government Department of Health; Cancer Australia; Prostate Cancer Foundation of Australia; Movember Foundation;
  • Travel and accommodation as invited speaker for support for professional and scientific conferences
  • Travel and accommodation as a member of professional and scientific advisory committees
  • Fees for contributions to book chapters
  • Participated in public submissions and development of position statements as a member of professional committees and board, on topics relating to euthanasia and physician assisted suicide, advance care planning, dementia, chronic diseases, workforce, medicinal cannibas, cancer service delivery, cancer care coordination, cancer workforce, psycho-oncology
  • Current member of advisory groups/ committees: AusHSI Management Committee; Movember Foundation International Prostate Cancer Health Outcomes Network; Movember Foundation Australian Prostate Cancer Health Outcomes Research Unit’s Research Advisory Board; Council of Deans of Nursing and Midwifery (Australia & New Zealand); Cancer Australia’s Steering Group for the Lung Cancer Demonstration Project; Cancer Australia’s National Research and Data Advisory Group; Caresearch National Reference Group; National Reference Group for the Discover TT (NHMRC CRE in Discovering Indigenous Strategies to Improve Cancer Outcomes Via Engagement, Research Translation and Training (DISCOVER-TT);
  • Previously member of a number of advisory/professional groups relating to health research, cancer, palliative care and nursing
  • Previously participated in advisory bodies for pharmaceutical companies on the following issues: 2000–2002 Janssen Cilag – Cancer related fatigue intiative 2001 Nursing Advisory Board, Amgen Australia 1999 National Pain Management Initiative, GlaxoWellcome,
  • Participated in an international project team to conduct a study on nurses' practices in managing chemotherapy induced nausea and vomiting, funded through an unrestricted educational grant provided by Merck to the International Society of Nurses in Cancer Care.
  • Honorarium provided by Novatis in 2006 for giving a lecture on developing a nursing research program
  • Published in journals and books in the following areas: palliative care; cancer care; nursing; symptom reduction; health services